

CORPORATE PROFILE


Precipio has built a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertise and technology developed within academic institutions and delivering quality diagnostic information to physicians and their patients worldwide. Through its collaborations with world-class academic institutions specializing in cancer research, diagnostics and treatment, Precipio offers a new standard of diagnostic accuracy enabling the highest level of patient care.

4 Science Park
New Haven, CT 06511
Phone: 1.203.787.7888
Fax: 1.203.901.1289
<http://www.precipiodx.com/index.html>
info@precipiodx.com

CORE IR
Scott Gordon
President
377 Oak Street
Garden City, NY 11530
516.222.2560
www.coreir.com
scottg@coreir.com

STOCK PERFORMANCE

Symbol	prpo
Exchange	NSC
Market Cap.	12.17m
52 Week Range	1.51 - 47.70
Close	1.94
Volume	47
Shares Outstanding	6,407,860
As of Oct 17, 2017 4:00 pm	



MANAGEMENT TEAM

Ilan Danieli - Founder & CEO

Carl Iberger - CFO

Stephen Miller - Chief Commercial Officer

Zaki Sabet - Chief Operating Officer

Ayman Mohamed - VP R&D

BOARD OF DIRECTORS

Mark Rimer - Director

Robert M. Patzig - Chairman of the Board of Directors

Ilan Danieli - CEO & Director

Michael A. Luther, Ph.D. - Director

Sam Riccitelli - Director

RECENT HEADLINES

[Oct 17, 2017 - Precipio's ICE COLD-PCR\(TM\) Technology Selected by the University of Kentucky for Liquid Biopsy Study](#)

[Oct 12, 2017 - Precipio Launches Its First Re-Designed ICE-COLD PCR\(TM\) Targeted Enrichment Kit To Identify Mutations in Lung Cancer Using Liquid \(Blood\) Biopsies](#)

[Oct 10, 2017 - Precipio Re-Launches All CLIA Lab and Pharmacological Research Projects at its New Haven, CT Facility](#)

[Oct 2, 2017 - Precipio Elects Jeffrey Cossman, MD, and Douglas Fisher, MD to its Board of Directors](#)

[Sep 6, 2017 - Precipio Provides Shareholder Update Letter](#)

PAST EVENTS

Sep 12, 2017 - 4:30pm Business Update Conference Call